🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Take a deep dive into the future of generative AI and drug discovery with Absci Founder and CEO Sean McClain. Catch his fireside chat tomorrow at Bloomberg Intelligence's Generative AI conference in NYC. Learn more and register here: bbgevent.app/gen-ai-scaling…

Stepping into the future of drug discovery! 📸 Excited to share a behind-the-scenes photo of Sean McClain, Founder and CEO of Absci, and AMD CTO Mark Papermaster as they record Episode 3 of Season 2 of Advanced Insights. Stay tuned for more.

Watch an on-demand replay of Absci Founder and CEO Sean McClain's fireside chat at Bloomberg Intelligence's Generative AI conference yesterday to learn how AI is making an impact on drug discovery and where it could potentially develop in the future: vimeo.com/1072275411/dec…

AI is revolutionizing protein engineering—from AlphaFold to GenMol, tools are accelerating drug discovery and sustainability. With players like Absci, Cradle, and Ginkgo Bioworks leading the way, the bioeconomy is being reshaped. Read the full article: 🔗synbiobeta.com/read/folding-t…

Season 2, Episode 3 of Advanced Insights is coming soon! Sean McClain, Founder and CEO of Absci, and AMD CTO Mark Papermaster step into the world of drug discovery, where processes are incredibly time consuming, costly and complex.

We’re seeking a Senior Scientist, Translational Research to join our mission to create better biologics for patients, faster. Learn more here: absci.com/job/?id=634648… #Absci #GenerativeAI #DrugDiscovery #Hiring #Jobs

Absci Founder and CEO Sean McClain joined AMD CTO Mark Papermaster on the latest episode of the Advanced Insight Podcast. Learn more about our partnership, recent applications of Absci’s de novo models, and more. youtube.com/watch?v=-MGp6h… #AI #Biologics #DrugDiscovery

AMD CTO Mark Papermaster sits down with Sean McClain, Founder and CEO of Absci, to discuss the future of drug discovery, and how AI is revolutionizing this process. Hear how AI is accelerating innovation, cutting costs, and paving the way for personalized medication. Tune in

We’re excited to present at the Festival of Biologics tomorrow at 3:00 PM PT in the AI and Machine Learning for Drug Discovery track. We hope to see you there!

Absci Founder & CEO Sean McClain is joining the Luke Timmerman Traverse to support the fantastic work of Life Science Cares in fighting poverty. This year’s team will be ascending 7,000 feet and covering 20 miles. Learn more: timmermanreport.com/2025/04/meet-t… #Absci #LifeScienceCares

Join Advanced Insights host Mark Papermaster and Sean McClain, Founder and CEO of Absci, as they discuss the future of patient treatment with AI. In the next 5+ years, AI advancements will enable drugs to be precisely targeted to individual patients, enhancing care and

We’ll be presenting our latest work at PEGS Boston! Join us on May 16th in the Machine Learning Approaches for Protein Eng. track to learn how we combine generative AI with scalable wet lab technologies to create better biologics for patients, faster. pegsummit.com

Absci is searching for a Director of Accounting to play a pivotal role in shaping the strategy and operations of our fast-paced, mission-oriented Finance organization. Come join us as we pursue our mission to create better biologics for patients, faster: absci.com/job/?id=654483…

Absci’s Founder and CEO Sean McClain spoke to ZDNET's Tiernan Ray about the Phase 1 clinical trial initiation of ABS-101, our AI-designed antibody for the treatment of IBD, and what’s next for AI Drug Creation. Read more here: zdnet.com/article/this-a… #AI #DrugDiscovery

We’ll be presenting at Antibody Engineering and Therapeutics Europe 2025, June 10-12 in Basel, Switzerland. Join our presentation “Fc Engineering to Improve Antibody Half-Life: AI-Guided and Rational Design” on June 12th at 12:00 PM. Learn more here: informaconnect.com/antibody-engin…

Absci Advances Lead AI-Designed Candidate for IBD into the Clinic The trial is designed to assess the antibody’s ability to treat IBD by targeting tumor necrosis factor-like cytokine 1A (TL1A). #IBD #ArtificialIntelligence Absci hubs.li/Q03pHrHy0

See why we are excited about the potential ABS-101, Absci’s first AI-designed biologic to enter the clinic, has to treat IBD, and get an update on some of the other assets in our growing pipeline in this deep dive with Genetic Engineering & Biotechnology News's Alex Philippidis. #AI #DrugDiscovery #Biologics

Absci becomes clinical-stage company with clinical trial initiation ddw-online.com/absci-becomes-… #ClinicalTrial